Galderma launched “We Are All Sculptra”, showcasing Sculptra’s regenerative versatility across diverse patient demographics. The programme tracks nine treatment-naïve participants over two years. It delivers longitudinal insights into tailoring regenerative biostimulation across ages, skin types, ethnicities, and aesthetic goals. Through structured clinical documentation, standardised imaging, and patient-reported video diaries, the initiative provides real-world evidence of outcomes in routine practice settings. ...
Galderma showcased significant updates across its dermatology portfolio at the 2025 American Academy of Dermatology (AAD) Annual Meeting. The company reinforces its leadership commitment in dermatology innovation with 22 scientific presentations, including two oral e-posters. Nemluvio Nemolizumab (Nemulizumab), Galderma’s treatment for prurigo nodularis and atopic dermatitis, was a key focus at AAD 2025. A new oral presentation showcases Nemluvio’s efficacy ...
Galderma marks the 25th anniversary of Sculptra® with new data and recent approvals, strengthening its leadership in regenerative aesthetics. Sculptra has been used to enhance skin rejuvenation, thanks to its unique formulation of poly-L-lactic acid (PLLA-SCA™). It has helped millions of people worldwide restore their skin’s natural radiance by working in harmony with the body’s own processes. As one of ...